Lv3
250 积分 2023-05-12 加入
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
7小时前
待确认
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment
7小时前
待确认
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
7小时前
已完结
Exploring Zanidatamab’s efficacy across HER2-positive Malignancies: a narrative review
7小时前
已完结
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer
7小时前
已完结
Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
5天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
6天前
已完结
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant
6天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
7天前
已完结
Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation
1个月前
已完结
皖公网安备34019202002308
